Interviews

[Interview] How COVID-19 Catalyzed AI-assisted Open Science Drug Discovery

by Andrii Buvailo, PhD  (contributor )   •     

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

Biopharma companies are now racing to find much-needed cures against SARS-CoV-2, a virus that caused the largest global pandemic of our time. One notable effort is the COVID Moonshot project, organized by an international consortium of scientists from academia, biotechs, contract research organizations (CROs), and pharma -- all working pro bono or via crowdfunding, philanthropy, and grants. 

The aim of the project is to rapidly develop easily manufacturable antiviral drugs that can inhibit the SARS-CoV-2 main protease, which is believed to be an Achilles heel of the coronavirus. The project is managed by PostEra, a startup company that uses artificial intelligence (AI) algorithms to map routes for chemical synthesis to speed the drug-discovery process.

#advertisement
AI in Drug Discovery Report 2025

Continue reading

This content available exclusively for BPT Mebmers

Topics: AI & Digital   

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

You may also be interested to read: